A method in vitro for: assessing the likelihood that a subject will benefit from treatment with an agent selected from the group consisting of an antiinflammatory agent, an antithrombotic agent, an antiplatelet agent, a fibrinolytic agent, a lipid lowering agent, a direct inhibitor thrombin receptor inhibitor of glycoprotein IIb / IIIa antibody adhesion molecule monoclonal or polyclonal anti-cell which inhibits the ability of leukocytes to bind to cell adhesion molecules, a blocker of calcium channel, one blocker beta-adrenergic receptor inhibitor, a cyclooxygenase-2 inhibitor and an inhibitor of the renin-angiotensin system wherein the method comprises: obtaining a first level of soluble protein IL1RL-1 in a sample of a subject comparing the level of the IL1RL-1 protein soluble at a specific default value for the diagnosis of a cardiovascular condition selected from myocardial infarction and heart failure, wherein the predetermined value is one boundary value, and wherein a level of the soluble IL1RL-1 protein or above the predetermined limit value is indicative of whether the subject will benefit from treatment with said agent.Un procedimiento in vitro para: evaluar la probabilidad de que un sujeto se beneficiará del tratamiento con un agente seleccionado del grupo que consiste en un agente antiinflamatorio, un agente antitrombótico, un agente antiplaquetario, un agente fibrinolítico, un agente hipolipemiante, un inhibidor directo de la trombina, un inhibidor del receptor de la glicoproteína IIb/IIIa, un anticuerpo de molécula de adhesión anti-celular monoclonal o policlonal que inhibe la capacidad de los leucocitos para unir a las moléculas de adhesión celular, un bloqueador del canal de calcio, un bloqueador del receptor beta-adrenérgico, un inhibidor de la ciclooxigenasa-2, y un inhibidor del sistema renina-angiotensina, en donde el procedimiento comprende: la obtención de un primer nivel de proteína IL1RL-1 soluble en una muestra de un sujeto la comparación de
